Skip to main content

Table 3 Participants classified as sarcopenic or having the metabolic syndrome at baseline and 12 weeks

From: Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

 

Baseline

Week 12

P*

Variable

n

%

n

%

Sarcopenia

 EXE

5

38.5

2

15.4

0.04

 NoEXE

9

47.4

10

52.6

 

MetS

 EXE

6

50.0

6

50.0

0.18

 NoEXE

7

36.8

8

42.1

 

MetS Suma

 EXE

2.8

1.4

2.8

1.5

0.54

 NoEXE

2.1

1.4

2.3

1.6

 
  1. Data presented as number of participants, % of participants, except where indicated by a(mean ± standard deviation); P, significance level; EXE, exercise groups (TRAINPRO and TRAIN); NoEXE, non-exercise groups (PRO and STRETCH); MetS, metabolic syndrome
  2. *Analysis adjusted for baseline values, protein supplementation, body mass index and number of comorbidities
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us